A study showed that a blocking anti-TRAIL monoclonal antibody, on the one hand, exacerbates murine experimental autoimmune encephalomyelitis, while recombinant TRAIL, on the other hand, suppressed disease [56]. This evidence concerns the gene TNFSF10 and experimental autoimmune encephalomyelitis.